Screener / SEC EDGAR /CIK 0000887359 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Biotechnology

Vericel Corp VCEL

Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. 10-K, Item 1

Headquarters
Burlington, MA
Next results
around Jan 12, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $276.3M through the costs to a net profit of $16.5M · income statement of the 10-K

4% operating margin
Revenue to Gross profit: $205.6MRevenue to Cost of revenue: $70.7MGross profit to Operating profit: $11.0MGross profit to Operating expenses: $194.6MOperating profit to Net profit: $10.2MOperating profit to Tax: $859KOther income to Net profit: $6.3MOperating expenses to R&D: $27.6MOperating expenses to SG&A: $167.0M Revenue: $276.3M REVENUE $276.3M +16% Y/Y Gross profit: $205.6M · 74% margin GROSS PROFIT $205.6M 74% margin · +19% Y/Y Cost of revenue: $70.7M · 26% of revenue COST OF REVENUE $70.7M 26% of revenue Operating profit: $11.0M · 4% margin OPERATING PROFIT $11.0M 4% margin · +144% Y/Y Other income: $6.3M · 2% of revenue OTHER INCOME $6.3M 2% of revenue Operating expenses: $194.6M · 70% of revenue OPERATING EXPENSES $194.6M 70% of revenue Net profit: $16.5M · 6% margin NET PROFIT $16.5M 6% margin · +59% Y/Y Tax: $859K · 0% of revenue TAX $859K 0% of revenue R&D: $27.6M · 10% of revenue R&D $27.6M 10% of revenue SG&A: $167.0M · 60% of revenue SG&A $167.0M 60% of revenue
Gross profit $205.6M 74% margin · +19% Y/Y
Operating profit $11.0M 4% margin · +144% Y/Y
Net profit $16.5M 6% margin · +59% Y/Y
The full income statement, year by year

VCEL among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 16.5%, above 68% of 154 peers (their median 10.4%) REVENUE GROWTH 16.5% · above 68% Gross margin: 74.5%, above 79% of 107 peers (their median 63.4%) GROSS MARGIN 74.5% · above 79% Operating margin: 8.3%, above 46% of 138 peers (their median 10.2%) OPERATING MARGIN 8.3% · above 46% Net margin: 10.3%, above 62% of 153 peers (their median 6.7%) NET MARGIN 10.3% · above 62% FCF margin: 17.9%, above 72% of 144 peers (their median 9.9%) FCF MARGIN 17.9% · above 72% Return on capital: 2.7%, above 8% of 89 peers (their median 9.2%) RETURN ON CAPITAL 2.7% · above 8%
VCEL Peer median Below the median

What changed

24 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +37.9% ($61.4M to $84.6M) vs revenue +16.5% ($237.2M to $276.3M), +21.4 pts apart
  • Cash from operations $51.9M vs net income $16.5M (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +1.1% ($17.4M to $17.6M) vs revenue +16.5% ($237.2M to $276.3M), -15.4 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Contractual Allowances Related to MACI Implant Sales Subject to Third Party Reimbursement
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

24 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 24 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Market acceptance of any future product candidates (including MACI Ankle, for which we initiated a clinical trial in the fourth quarter of 2025), if approved, will not be fully known until after they are launched and may be negatively affected by a
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    If we do not effectively expand and train our direct sales force, we may be unable to add new customers or increase sales to our existing customers, and our business will be adversely affected. During 2025, we began an expansion of our MACI sales force. Our ability to achieve significant revenue growth will depend, in large part, on our…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Additionally, several of our ongoing clinical trials utilize an “open-label” trial design. An “open-label” clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Under the Orphan Drug Act, the FDA may grant orphan designation to drugs or biologics intended to treat a rare disease or condition, generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or affects more than 200,000

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$164.4M$197.5M$237.2M$276.3M
Net income−$16.7M−$3.2M$10.4M$16.5M
Operating cash flow$17.7M$35.3M$58.2M$51.9M
Free cash flow$10.1M$15.3M−$5.8M$24.7M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$276.3M ▲ 16.5% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

16 filings in the last 30 days · SEC EDGAR

All filings
11 more

About the company

Vericel Corp, Burlington, MA · from the 10-K filed Feb 26, 2026

Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S.

Headquarters
Burlington, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
MI

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.